Anti-PD-1/PD-L1 antibodies alone in monotherapy or combined with anti-CTLA-4 antibodies or different chemotherapy agents have demonstrated unprecedented clinical efficacy and durable responses in more than 15 cancer types in the advanced setting [1,2]. This evidence concerns the gene CTLA4 and cancer.